In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Abbott licenses MedImmune's MEDI-493

Executive Summary

Abbott Laboratories has acquired exclusive rights outside of the US to MedImmune's MEDI 493 (palivizumab) to treat respiratory syncytial virus (RSV). Within the US, the company's Ross division will co-promote it with MedImmune.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Manufacturing or Supply
    • Marketing (Licensing)

Related Companies